0.00Open21.50Pre Close0 Volume0 Open Interest100.00Strike Price0.00Turnover0.00%IV2.02%PremiumDec 27, 2024Expiry Date19.88Intrinsic Value100Multiplier3DDays to Expiry1.62Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.90Leverage Ratio--Theta--Rho--Eff Leverage--Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
No comment yet